Synergy of CD95 ligand and teniposide: No role of cleavable complex formation and enhanced CD95 expression
- 1 January 1998
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 341 (2-3) , 323-328
- https://doi.org/10.1016/s0014-2999(97)01478-7
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?Journal of Clinical Investigation, 1997
- Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeuticsCancer Immunology, Immunotherapy, 1997
- Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.Journal of Clinical Investigation, 1997
- Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cellsNature Medicine, 1996
- Structure and mechanism of DNA topoisomerase IINature, 1996
- Genetic Regulation and Therapeutic Modulation of Apoptosis in Human Malignant GliomaCellular Physiology and Biochemistry, 1996
- The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-?, T-cell apoptosis, and the immune privilege of the brainBrain Research Reviews, 1995
- Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivoEuropean Journal of Immunology, 1995
- Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.Journal of Clinical Investigation, 1994
- Lethal effect of the anti-Fas antibody in miceNature, 1993